Andalus, a compound preparation for adult type 2 diabetes, is listed in China
jack_hua
发表于 2023-11-24 11:43:44
3632
0
0
AstraZeneca has recently announced the release of Andaishi& Reg; (Common name: Daggligin Metformin Sustained Release Tablets) This compound preparation for type 2 diabetes is marketed in China. It is reported that, as the only compound preparation of SGLT2 inhibitor and metformin hydrochloride sustained-release agent that takes a fixed dose once a day in China, daggligin metformin sustained-release tablets provide a first-line treatment option for improving blood glucose control in patients with type 2 diabetes.
The Guidelines for the Prevention and Treatment of Type 2 diabetes in China (2020 Edition) points out that the short-term goal of diabetes treatment is to eliminate the symptoms of diabetes and prevent acute complications by controlling hyperglycemia and metabolic disorders, and the long-term goal is to prevent cardiorenal complications, improve the quality of life of patients and extend life through good metabolic control.
Professor Ji Linong, from Peking University People's Hospital, said that the arrival of daggligin metformin sustained-release tablets provided a new treatment method of "one scheme, double protection" for the achievement of short-term and long-term goals of diabetes treatment.
Professor Zou Dajin from Tongren Hospital affiliated with Shanghai Jiao Tong University School of Medicine believes that the two complementary mechanisms of action of Daggliflozin metformin sustained-release tablets help simplify treatment plans and improve patient treatment compliance.
Lai Minglong, general manager of AstraZeneca China, said that improving blood glucose control rate and reducing heart and kidney complications are important tasks for the prevention and treatment of diabetes in China, and hoped that the application of daggligin metformin sustained-release tablets would be accelerated in China.
Wen/Guangzhou Daily · New Flower City Reporter Tu Duanyu
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Lilly is reported to have reached a cooperation agreement with two pharmaceutical companies regarding the filling of injection pens
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion RMB in the expansion project of sterile preparations in Tianjin
- Novo Nordisk invests approximately 4 billion yuan in the expansion project of sterile preparations in Tianjin
- 4 billion yuan! Novo Nordisk launches aseptic formulation expansion project
- The world's first weekly insulin preparation has encountered setbacks in the United States, and the FDA requires additional information, with no hope of approval this year
-
【英偉達の需要が高すぎる?SKハイニックス:黄仁勲がHBM 4チップの6カ月前納入を要求!】SKハイニックスの崔泰源(チェ・テウォン)会長は月曜日、インビダーの黄仁勲(ファン・インフン)CEOが同社の次世代高帯域 ...
- 琳271
- 前天 17:54
- 支持
- 反对
- 回复
- 收藏
-
ファイザーが前立腺がんを治療する革新薬テゼナ& ;reg;(TALZENNA®,一般名:トルエンスルホン酸タラゾールパーリカプセル)は2024年10月29日に国家薬品監督管理局(NMPA)の承認を得て、HRR遺伝子突然変異 ...
- 什么大师特
- 昨天 17:41
- 支持
- 反对
- 回复
- 收藏
-
南方財経は11月5日、中央テレビのニュースによると、現地時間11月5日、米ボーイング社のストライキ労働者が59%の投票結果で新たな賃金協定を受け入れ、7週間にわたるストライキを終えた。ストライキ労働者は11月12 ...
- Dubssgshbsbdhd
- 昨天 16:27
- 支持
- 反对
- 回复
- 收藏
-
【マスクはテスラが携帯電話を作ることに応えた:作れるが作らないアップルとグーグルが悪さをしない限り】現地時間11月5日、有名ポッドキャストのジョローガン氏のインタビューに応じ、「携帯電話を作るのは私たち ...
- 波大老师
- 昨天 14:41
- 支持
- 反对
- 回复
- 收藏